To clarify the potential effect of ponatinib on metabolic disorders during obesity, ponatinib was orally administered to leptin-deficient (ob/ob) mice and the control mice (lean) once-daily for 8 weeks (Figure 1A). Here, LEP is linked to metabolic disease.